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In December 2019, the World Health Organization (WHO) was informed of an outbreak of an 
unknown cause of pneumonia-like symptoms in residents concentrated in Wuhan, China; this 
marked the start of China’s epidemic, which transformed into a pandemic affecting all continents 
of the world. The cause of the pneumonia-like symptoms was found to be due to the growth and 
development of the virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which 
spreads through an infected person’s respiratory droplets through activities such as talking, 
coughing, and sneezing. With COVID-19 vaccine manufacturers available worldwide, even the 
economically and technologically forward countries such as Thailand and China contain pockets 
of residents without access to the COVID-19 vaccine to this day.  
Objective 
This paper will examine the potential use of herbal and medicinal plants as a form of treatment in 
mitigating mild to moderate COVID-19 symptoms in diagnosed COVID-19 positive residents in 
Thailand and China.  
Methods 
A comprehensive literature review was performed using PubMed and references cited in 
UpToDate. Seven articles that focused on the topic were chosen for a narrative review. Based 
upon the research literature, a proposal for further mixed-method study is presented.  
Keywords: Epidemic, pandemic, COVID-19, SARS-CoV-2, China, Thailand, 
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In December 2019, the World Health Organization (WHO) was informed of an outbreak 
of an unknown cause of pneumonia-like symptoms in Wuhan, China residents; this marked the 
start of China’s epidemic, which in the blink of an eye transformed into a pandemic affecting all 
continents of the world (McIntosh et al., 2021). The cause of the pneumonia-like symptoms was 
due to the severe acute respiratory syndrome coronavirus 2 virus (SARS-CoV-2) which spreads 
through an infected person’s respiratory droplets through activities such as talking, coughing, 
and sneezing. With these droplets being viable for up to a few days, the WHO emphasized the 
importance of maintaining a physical distance of at least six feet, wearing a facial covering over 
the nose and mouth, and strict hand hygiene as crucial steps in preventing the spread of 
coronavirus disease of 2019 (COVID-19).  
Although a handful of vaccine manufacturers worldwide have surpassed the research and 
development phase and produced their formulated vaccine to combat the rapid spread of 
COVID-19, even the economically and technologically forward countries such as Thailand and 
China to this day contain pockets of residents without access to the COVID-19 vaccine. 
Therefore, the purpose of this literature review and proposal for further study is to explore the 
potential for Chinese and Thai herbal therapies to manage mild to moderate COVID-19 
symptoms.  
The research question is: 
What is the efficacy of native Thai and Chinese herbal and medicinal plants as a 
nonpharmacological intervention in mitigating mild-to-moderate COVID-19 symptoms for 




 In this narrative literature review, seven articles were obtained from databases such as 
PubMed and UpToDate. The objective of this process is to identify articles demonstrating the 
efficacy of herbal and medicinal plants native to China and Thailand in mitigating mild to 
moderate COVID-19 symptoms. The articles found were narrowed by the year of publication, 
type of research the literature was categorized as, and region the literature is concentrating on. 
The acceptable time range of published studies needed to fall within December 2019 (start of the 
COVID-19 widespread) until the current day (November 2021). The last search strategy used 
pertains to the studied region, which for this particular literature review is focused on Thailand 
and China.  
The search terms used included terms such as herbal plants, medicinal plants, COVID-19, 
traditional Eastern medicine, Thailand, China, SARS-CoV-2, antiviral, treatment, prevention, 
herbal, traditional Chinese medicine, ethnobotany, mild COVID-19 symptoms, mild to moderate 
COVID-19 symptoms, moderate COVID-19 symptoms, meta-analysis, systematic review, 
coronavirus, and anti- SARS-CoV-2. An example of a search entry used on PubMed was 
COVID-19 [OR] SARS-CoV-2 [AND] China [OR] Thailand [AND] herbal plants [OR] 
medicinal plants [AND] treatment. 
In the process of sifting through the databases available through Dominican University of 
California’s library webpage, PubMed, UpToDate, Cochrane Library, and the US National 
Library of Medicine National Institute of Health (PMC) yielded the most relevant information 
regarding the proposed topic. Seven articles selected by the mentioned criteria were chosen to 
support the research questions posed regarding the efficacy of herbal and medicinal plants native 
to China and Thailand in relieving mild to moderate COVID-19 symptoms are organized into 
7 
three categories: herbal and medicinal plants used to mitigate mild to moderate COVID-19 
symptoms in Thailand, China, and studies of adaptations made to traditional Chinese medicine 
used for COVID-19 patients. 
The Use of Herbal and Medicinal Plants Native to Thailand for Mitigating Mild to 
Moderate COVID-19 Symptoms 
From January 3, 2020, to October 18, 2021, COVID-19 cases in Thailand ranks 24 of 
223, and 69.8 million people in 2020, there were 1,793,812 reported positive COVID-19 cases, 
1,668,250 recoveries, 18,336 deaths, and 10,111 daily new cases (Thailand: Who coronavirus 
disease (covid-19) dashboard with vaccination data, n.d.). In terms of COVID-19 vaccination 
status, although 59,258,667 vaccine doses have been administered, 35,462,170 people have been 
vaccinated with at least one dose and 23,796,497 are considered as fully vaccinated (dependent 
on the vaccine manufacturer). Three articles were chosen to demonstrate the use of herbal and 
medicinal plants in Thailand by identifying which species of plants contain anti-SARS-CoV-2 
mechanisms, which parts of the plant have the highest antiviral effect, and uses among Thai 
Karen and Hmong residents. 
The article titled, “High-content screening of Thai medicinal plants reveals Boesenbergia 
rotunda extract and its component Panduratin A as anti-SARS-CoV-2 agents” details the 
extensive work to develop a high-content screening method for potential antiviral plants 
(Kanjanasirirat et al., 2020). The researchers used SARS-CoV-2 nucleoprotein detection to 
measure the amount of plaque reduction assay and dose-response analysis to indicate the 
effectiveness of the identified herbal and medicinal plants in viral suppression. With a sample 
size of 122 Thai medicinal plants, the researchers developed a quantitative experimental research 
design using a two-step approach: pre-entry and post-infectious treatments. The pre-entry 
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approach of the quantitative experiment was described as pre-incubating each of the Thai herbal 
plants’ natural extracts with the SARS-CoV-2 virus strain into a test tube before being 
inoculated. The post-infectious portion of their experiment was carried out by introducing the 
natural extracts to the cell culture after viral infection in which the effectiveness of the viral 
suppression activity was observed for the duration of the experiment.  
Of the three plant extracts experimented on, Panduratin A (extract named B. rotunda) 
demonstrated the highest inhibitory concentration against the SARS-CoV-2 virus during both the 
pre-entry and post-infection phase as well as successfully suppressing viral growth when 
exposed to extracted human’s airway epithelial cells in a controlled manner. Three main 
strengths were identified: the results from their study were thoroughly performed and collected 
as they measure the outcome of the chosen medicinal plants through both dose-response 
relationship and plaque assay reduction, a large study sample of one hundred twenty-two 
potential native Thai medicinal plants to be tested were studied in detail in preparation for their 
experiment, and beyond testing the impact of the B. rotunda extract from the Panduratin A plant 
on the post-infection phase, the researchers expanded their study and tested whether the two 
components would have an effect for pre-entry treatment which also showed successful results. 
One major limitation the authors stated about their product was, “it has prompted us to develop, 
for the first time, a high-content screening platform” which indicates a possible lack of 
credibility with the results found as their same study has not been able to be replicated by others 
in a way to obtain the same experimental results (Kanjanasirirat et al., 2020, pg. 2).  
The next article to be included in this comprehensive literature review is “Rapid selection 
of Andrographis paniculata medicinal plant materials based on major bioactive using near-
infrared spectroscopy” which is a quantitative study focusing on developing experimental 
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research that determines the efficacy of the Andrographis paniculata Thai medicinal plant on its 
antiviral activity against SARS-CoV-2. For this study, one hundred and seventy samples 
(collected from ten provinces of Thailand including Bangkok, Nakhon Pathom, Nonthaburi, 
Prajeenburi, Phetchaburi, Phetchabun, Mahasarakham, Suphanburi, and Sa Kaeo) of the plant 
were obtained over two years which were categorized into four groups: aerial, stems, leaves, and 
stems mixed with leaves (Kasemsumran et al., 2021). Fresh samples of the Andrographis 
paniculata plant were made into a powder form being dried at 50 degrees Celsius for ten hours 
and then mechanically ground, then placed into their respective test tube for near-infrared 
spectrophotometer (NIR) testing.  
The NIR technique was chosen by the researchers as the plants did not have to be 
extracted prior and had the lowest risk of destroying or tampering with the sample in the process. 
Additionally, because of the difficulty in distinguishing the parts of the plant after thorough 
grinding, this was another reason which prompted the researchers to create an experiment to 
quantify the contents with the NIR banding method. The Partial Least Squares-Discriminant 
Analysis method (PLS-DA) showed success in classifying the results in the controlled and 
experimental test tubes. From the different plant parts included in the experiment, the leaves only 
test tubes were found to yield the highest content of bioactive compounds as well as 
andrographolide (AP1) whereas in the test tubes which contained a mixture of the Andrographis 
paniculate leaves and arterial parts contained the highest amount of dehydroandrographolide 
(AP3). AP1 is a chemical compound that interferes with the reproduction of malignant cells such 
as those replicated by the SARS-CoV-2 virus, while AP3 is found to be an anti-inflammatory 
and antiviral agent.  
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 The last article which magnifies the use of native Thai herbal and medicinal plants in 
mitigating mild COVID-19 symptoms is “Medicinal Plants Used for Treating Mild Covid-19 
Symptoms Among Thai Karen and Hmong”. This study includes a compiled literature review 
and qualitative study executed in the form of field interviews with a total of 1,230 use reports of 
medicinal plants among residents in the Thai Karen (555 reports) and Hmong (675 reports) 
communities with mild COVID-19 symptoms (Phumthum et al., 2021). Additionally, sixteen 
local healers were included in this study as they primarily use medicinal herbs and ethnobotany 
practices to treat the symptoms experienced. Four hundred ninety-one plant species were 
identified among the Thai Karen and Hmong communities to alleviate symptoms of fever 
(commonly Acorus calamus, Strobilanthes cusia, and Melicope glomerata), cough (commonly 
Zingiber officinale, Blumea balsamifera, and Elephantopus scaber), and diarrhea (Psidium 
guajava and Zingiber ottensii) labeled as mild COVID-19 symptoms by the World Health 
Organization (WHO).  
With the rapid spread of COVID-19 worldwide, identification of these plants native to 
Thailand provides significant information which could alleviate the strain on healthcare workers, 
institutions, as well as benefit residents in Thailand who may be isolated due to living situations 
or access to healthcare and the COVID-19 vaccine. 
Using Traditional Chinese Medicine Alongside Western Medicine 
Examining the Use of Integrative Medicine: Using Traditional Chinese Medicine Alongside 
Western Medicine  
 From January 3, 2020, to October 18, 2021, China ranks 133 of 223 as there have been a 
total of 125,254 confirmed cases, 5,695 deaths, and a total of 2,228,305,003 vaccine doses 
administered (1,014,573,856 people being fully vaccinated) (China: Who coronavirus disease 
(covid-19) dashboard with vaccination data, n.d.). To examine the use of integrative medicine 
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using traditional Chinese medicine (TCM) alongside conventional Western medicine (CWM), 
two primary articles demonstrate the benefits of using both practices concurrently for better 
outcomes in patients diagnosed with COVID-19.   
“Chinese herbal medicine for coronavirus disease 2019: A systematic review and meta-
analysis” summarizes the results of eighteen randomized controlled trials on 2,275 COVID-19 
positive patients using traditional Chinese herbal medicine in mainland China (Xiong et al., 
2020). Two groups were studied: the control group receiving conventional Western medicine 
and/or a combination of Chinese herbal medicine placebo while the treatment (experimental) 
group was treated by Chinese herbal medicine and/or alongside conventional Western medicine. 
To ensure continuity in the interventions between the two groups, the medication used for the 
Western medicine practice was given by the same dosage, route of administration, and usage. 
The experimental results were primarily monitored in the form of multiple lung CT scans 
throughout the study period and measuring the clinical cure rate, length of hospital stay, and 
pertinent inflammatory biomarkers which snapshot the patient’s recovery such as white blood 
cells, lymphocytes, C-reactive protein, and neutrophils.  
From this experiment, the risk reduction (RR) for lung CT improvement among 749 the 
experimental Chinese herbal medicine (CHM) and 653 controlled conventional Western 
medicine (CWM) participants was 1.23, death in 256 CHM and 207 CWM showed a RR of 0.34 
or indicating very little difference, and clinical symptoms (including sore throat, dry throat, chest 
tightness, fever, and fatigue) were shown to be significantly improved through the use of scoring 
the individual’s clinical symptoms. To gain a deeper understanding of the use of integrative 
medicine, the risk reduction rate was compared between the CHM (experimental) and CWM 
(controlled) groups that showed significant improvement in cough among 240 CHM and 182 
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CWM participants of an RR value of 1.50, fever being significantly reduced within 433 patients 
with a weight mean difference of -0.60, fatigue reduction among 167 patients in CHM and 140 in 
CWM with a RR value of 1.73, TCM syndrome reduction within 141 CHM participants with a 
weight mean difference of -6.60. In terms of the laboratory markers monitored throughout the 
study, although there were no significant differences in the two groups in improving white blood 
cell and lymphocyte count, in six trials the C-reactive protein showed a significant reduction in 
the experimental group with a weight mean distribution of -8.91. Lastly, for participants to be 
considered for discharge from the hospital, the clinical cure rate which includes four sub criteria 
must be completed: significantly improved respiratory symptoms, completing two COVID-19 
tests at least one day apart from each other which showed negative results, stabilizing and return 
of body temperature within normal limits for at least three days, and results from the CT scan 
which showed decreased inflammation of the pulmonary system. Of 1,523 participants, including 
760 from the CHM and 763 from the CWM group, yielded a risk reduction rate of 1.18 in those 
receiving the combination of traditional Chinese medicine alongside conventional Western 
medical interventions.  
The second article demonstrating adaptations made to TCM is titled, “Efficacy and safety 
of Integrated Traditional Chinese and Western medicine for Coronavirus disease 2019 (COVID-
19): A systematic review and meta-analysis” (Liu et al., 2020). The purpose of the study was to 
determine the efficacy and safety of using Traditional Chinese Medicine alongside Western 
Medicine for COVID-19 patients also known as “integrative medicine”. For this study, 982 
participants (ages 18 or older and clinically diagnosed with COVID-19) were included in the 
control and experimental groups with studies ranging from 5 to 30 days with an average of 13.55 
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days. Due to the ranging treatment time frames, this potentially hinders the results obtained as 
the participants did not receive the treatment for an equal duration of time.   
Four of the studies were randomized controlled trials and seven were case-control studies 
which were assessed using the Cochrane Risk of Bias tool and Newcastle-Ottawa Scale 
respectively. Patented Chinese medicine used for this trial includes Shufeng Jiedu Capsule, 
Lianhua Qingwen granules, and QingFei TouXie FuZhengFang. The practices of Western 
medicine incorporated in this study include respiratory assisted ventilation, antiviral agents such 
as lopinavir and abidol, supportive care, and glucocorticoid therapy to inhibit inflammation. 
Participants in the control group only received modern Western treatments for COVID-19 
symptoms, while the experimental group received the integrated medicine practice of combining 
TCM and Western medicine.  
In terms of quantitative-wise, the risk ratio value (RR) was used for testing factors which 
fell into the dichotomous data category of having two categories of outcomes, while the 
weighted mean difference (WMD) was used for continuous testing factors such as the hospital 
stay which could result in a large range of outcomes such as a couple of days to years. 
Participants in the experimental group who received the integrated medicine treatment had an 
overall better outcome than the control group for the following categories: response (RR= 
1.230), severity of illness (RR=0.350), cure (RR=1.604), and hospital stay rate (WMD= -1.991). 
About interpreting the risk ratio, the cure rate which resulted in a score of 1.604 means the odds 
of the outcome in participants receiving the integrated medicine treatment are 1.604 times the 
odds of the outcome happening in the controlled group (those who received a placebo) to be 
cured of COVID-19. The use of integrated medicine for this particular group of patients showed 
the ability to mitigate symptoms of cough, fatigue, anorexia, fever, fatigue time, chest tightness, 
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and sputum production from the lungs or throat from coughing. Although clinical symptoms 
which are deemed as subjective data were collected from the participants, other objective data 
indicators were included such as measuring the C-reactive protein count, white blood cell, 
lymphocyte percentage, and tumor necrosis factor-alpha. This study is the beginning of many 
potential research topics regarding integrated medicine for diagnosed COVID-19 patients.  
Overall, these two studies demonstrated the positive outcome of integrated medicine as 
opposed to solely Western medicine in the treatment regimen for COVID-19 positive patients in 
relieving the category of symptoms mentioned earlier such as fever and cough along with 
improving the patient's laboratory indicators, specifically the lymphocyte percentage and 
interferon-alpha levels back to within normal limit ranges. 
Adaptations to Traditional Chinese Herbal Medicine for Use to Improve COVID-19 Patient 
Outcomes 
Two articles were chosen to demonstrate the adaptations to the use of traditional Chinese 
herbal medicine which has been thoroughly studied to improve COVID-19 patient outcomes. 
The adaptations made to Eastern medicine include providing the herbal and medicinal plants 
native to China in a form of an injectable treatment while examining the potential treatment for 
COVID-19 symptoms by providing a dual treatment of Chinese herbal medicine alongside 
Western medicine.  
In the article, “A real-world study on adverse drug reactions to Xuebijing Injection: 
Hospital intensive monitoring based on 93 hospitals (31,913 cases)” the authors determined the 
efficacy and safety of traditional Chinese medicine injections on patients located in China 
diagnosed with community-acquired pneumonia, regardless of age and gender (Zheng et al., 
2019). Although their population of interest seems to be very broad, they narrowed down the 
participants who would qualify to take part in this study by having either of the criteria listed. 
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For example, to be declared as a “critically severe patient” they have to either have one of the 
listed: respiratory failure requiring mechanical ventilation, shock, or organ failure needing 
intensive care unit monitoring and treatment. Although this paper focuses on the effects of 
COVID-19 on patients, it is important to note the significant correlation between those with 
COVID-19 (experiencing mild to moderate respiratory symptoms) have a higher risk of 
developing pneumonia and can even experience severe complications diagnosed as pneumonia.  
With randomized controlled trials being conducted, 31,913 participants from 93 hospitals 
(within August 2013 to August 2016) were divided into three groups: those who received no 
treatment, a placebo, or were given an injection as the active treatment. The TCM injections used 
in reducing community- acquired pneumonia symptoms include the Xiyanping, Xuebijing, 
Reduning, Tanreqing, Xingnaojing, Shenfu, Shengmai, and Shenmai injection. From their study, 
34 community-acquired pneumonia patients treated with the Chinese traditional injectable 
medicine alongside receiving Western medicine before admission showed better recovery 
outcomes. A major finding was that the Xuebijing injectable in particular enabled absorption of 
pulmonary lesions and decreased the risk of patients with pneumonia from experiencing a septic 
shock. Although the Xuebijing injectable yielded many positive results, there has not been any 
research on whether it is effective on inflammation reduction and negative transformation of 
nucleic acid as well as having a total of 96 adverse reaction cases to the Xuebijing injection 
which equates to 0.3% of their total sample size.  
Another article that focuses on determining the effectiveness of the Xuebijing injection 
for diagnosed COVID-19 patients is named, “Effect of Xuebijing Injection on Inflammatory 
Markers and Disease Outcome of Coronavirus Disease 2019” (Wen et al., 2020). Sixty clinically 
diagnosed COVID-19 patients in severe conditions admitted to the Changsha Public Health 
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Treatment Center in Changsha, China between January and March 2020 were divided into three 
groups for this study. Before taking part in the study, the chosen participants had their blood 
work taken to measure the pre- and post-treatment (taken eight days after the treatment course) 
levels of C-reactive protein, acute physiology and chronic health evaluation II (APACHE II) 
score, erythrocyte sedimentation rate, and COVID-19 test. The sixty participants were evenly 
divided into three groups (each with twenty participants): the control group who received the 
routine treatment for COVID-19, Xuebijing 50mL injection, and Xuebijing 100mL injection. 
Across the three groups, after the treatment period was completed, a decrease in C-reactive 
protein and erythrocyte sedimentation rate was observed, while the lymphocyte and white blood 
cell count increased. Overall, participants receiving the Xuebijing 100mL injection had more 
significantly improved results in the laboratory indicators mentioned above as well as their 
APACHE II score which was lower than the control and Xuebijing 50mL participants.  
Summarizing the Findings  
 Each of the studies included in this literature review has demonstrated positive and 
promising results regarding the use of herbal and medicinal plants native to China and Thailand 
to mitigate mild to moderate COVID-19 symptoms experienced in the qualified participants. 
Beyond confirming the efficacy of Chinese and Thai herbal plants in diagnosed COVID-19 
patients, a few studies have shown even better results when combining the practice with Western 
medicine. The findings summarized can be used to further healthcare practices, although further 
research would need to be conducted as many of the screening components used in the studies 
published have been the first to be produced in the field to detect the safety and efficacy of the 
Thai and Chinese herbal plants among COVID-19 patients. This creates a major limitation in the 
results gained from the literature sources as many studies were unable to be replicated to obtain 
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the same results due to time restraints and this matter being a recent topic of discussion in the 
healthcare field. For further information regarding the articles used, please refer to Appendix A 
for the summary of each literature review.  
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Proposal for Further Study 
 Although an immense amount of information was gained from the literature that was 
reviewed, there are apparent gaps in the research. The use of herbal and medicinal plants for 
mitigating COVID-19 symptoms is a fairly recent topic of discussion in the healthcare field. 
However, the majority of research in the review focused on the patient in the hospital setting. 
Therefore, a study is proposed to determine the efficacy of the native Chinese and Thai 
medicinal plants for mitigating COVID-19 respiratory symptoms among residents of rural areas 
of China and Thailand. The main research questions are: 
● How do specific species of medicinal plants, native to China and Thailand, perform in 
terms of mitigating mild respiratory symptoms, specific COVID-19, when used by 
residents of China and Thailand who live in rural areas?  
● How do the Chinese and Thai herbs compare to each other in regard to mitigating 
patients' mild COVID-19 respiratory symptoms? 
Theoretical Framework  
The proposed study will expand based on the germ theory, a theory brought up by Robert 
Koch which structured the research carried out by Louis Pasteur (A Theory of Germs, 2004). 
The four Koch postulates describe the relationship of microscopic organisms as the cause of 
disease in the host: (1) The microorganism must be found in diseased but not healthy individuals; 
(2) The microorganism must be cultured from the diseased individual; (3) Inoculation of a 
healthy individual with the cultured microorganism must recapitulate the disease; and (4) The 
microorganism must be re-isolated from the inoculated, diseased individual and matched to the 
original microorganism (Segre, 2013, pg. 2141-2142). In relation to COVID-19, the germ theory 
provides an excellent foundation demonstrating how the SARS-CoV-2 virus is responsible for 
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the COVID-19 disease. Additionally, the SARS-CoV-2 virus spreads through airborne particles 
from an infected person’s respiratory droplets through the body of healthy and susceptible hosts 
creating manifestations such as respiratory distress, fever, chills, sore throat, and new loss of 
taste and/or smell.  
This theory follows under the Western or biomedical system (as opposed to the 
magicoreligious and naturalistic health systems) which describes the cause of disease as being a 
result of abnormalities in the function of organs and body systems due to invasion of germs. 
Interestingly, people in rural China and Thailand, may not identify the changes in health that 
they experience with the SARS-CoV-2 virus as a communicable disease and not acknowledge 
that there is a world-wide pandemic.  
Primary Research Aims 
The primary research aim for this proposed quasi experimental study (to be approved by 
the Institutional Review Board [IRB]) is to determine the efficacy rates of native Thai and 
Chinese medicinal plants in mitigating respiratory-specific COVID-19 symptoms. Other aims of 
this study are to identify the benefits of herbal and medicinal plants as a practice in treating 
COVID-19 positive patients residing in rural Thailand and China areas where medical resources 
are limited and isolated. 
Ethical Considerations 
Interested participants will be informed by an IRB approved designee regarding the 
study’s purpose, risks, benefits, research approach, and alternatives to participation concerning 
the use of medicinal plants as a form of treatment for mild COVID-19 respiratory symptoms. 
Potential participants will then be provided sufficient time to ask the researchers questions 
related to the study and consider involvement prior to signing an informed consent which can be 
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removed at any time of the study and will not hinder them in any way. As this study engages 
with a vulnerable population group, participants will be informed of the risk and benefits and 
protective measures will be taken to ensure the adverse risk is low through implementing 
interventions which strictly follow the research design approved by the IRB to minimize 
unnecessarily exposing participants to risk, while promoting beneficence, nonmaleficence, and 
the participant’s autonomy throughout the study. 
To establish the confidentiality of our participants, study identifiers will be used 
throughout the preparation and duration of the experiment. A master document of the 
participant’s name and their respective study identifiers will be secured on a password-protected 
computer. To ensure the security of the documents used for this study, all files will be locked 
with a password and documents will be encrypted when embedded into emails. Additionally, 
only researchers in direct contact and working with the study participants will be discussing the 
inputs, outputs, outcome, and goal for this study, while also ensuring that researcher bias is 
minimized by strictly following the research plan and implementing parameters to reduce bias 
(such as the triangulation method to increase validity and credibility of the research findings). 
Research Method  
Research Design 
 The design of this proposed research study will be carried out in a mixed manner, having 
components of qualitative and quantitative study.  
Research Population and Sample Size 
A total of 1,500 participants will be recruited throughout rural China (750 residents) and 
Thailand (750 residents) to be included in the study. The criteria to be used are as follows: 
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between the ages of 18 and 65 years old, clinically diagnosed with COVID-19, and residing in a 
geographically determined rural area in either Thailand or China, without any limitations on 
nationality and gender.  
Strategy for Recruitment 
As this study is aimed to work with residents in rural areas of China and Thailand, they 
tend to have limited resources and are isolated from hospitals and local clinics. The strategies 
used for the recruitment of participants will be through snowball sampling. The researchers will 
form a healthcare team and partner with a mobile clinic that travels throughout the countryside 
and local public health nurses to inform the residents they are supporting when visiting their 
homes for health check-ups or providing COVID-19 testing. 
Statistical Analysis for Quantitative Research 
A randomized controlled trial will be used to categorize the qualified participants into 
one of three groups (each consisting of 500 participants): a controlled group of participants 
receiving the placebo treatment, an experimental group receiving a Thai medicinal herb, and 
another experimental group receiving a Chinese medicinal herb to test the efficacy of the 
specified herbal plants as a form of treatment in mitigating respiratory specific COVID-19 
symptoms among residents in rural areas of China and Thailand.  
A mobile clinic with a healthcare team will be used in each country to visit the rural 
communities targeted for participation. The mobile health clinic trailer will contain x-ray and CT 
imaging equipment. The primary pre- and post-experimental indicators used to determine and 
compare treatments in this study include a chest x-ray and/or lung CT scan to determine initial 
lung damage, real-time polymerase chain reaction (PCR) diagnostic panel, a complete blood 
22 
count panel, and other laboratory values such as white blood cell count, erythrocyte 
sedimentation rate, prothrombin time. With data collected from the three groups, an analysis of 
variance (ANOVA) will be used to compare the statistics obtained. Each arm of the study 
(Control, Chinese Herb, and Thai Herb) is expected to run from seven to 30 days and participants 
will be completing a daily survey ranking the intensity of their dyspnea, pain, and tiredness on a 
numerical rating scale of 0 to 10 (ordinal data) to be analyzed using ANOVA.  
Content Analysis for Qualitative Research 
Pre- and post-study semi-structured interviews through focus groups (5-8 participants) 
will be conducted by researchers working directly with this experiment to document the 
participant’s own experiences, biases, and concerns. Before the interviews, participants will be 
asked for consent to use information obtained and transcribed into a transcript to be included as 
study data. Examples of the questions to be included in the interview are as follows: 
1. Where is the closest clinic or hospital located? How many minutes away is the site?  
2. What do you call this “health change” (i.e. the COVID-19 pandemic)?  
3. How would members of your culture treat this condition (i.e. treat symptoms related to 
the virus)?  
4. What symptoms are you feeling and how long have you been experiencing them?  
5. How has your experience with the use of herbal and medicinal plants compared to your 
usual practices? 
In terms of the content analysis for qualitative research, the researchers will search for similar 
words and phrases throughout all of the focus groups to be organized into categories and 
subunits to identify common themes (Fain, 2021, pg. 212).  
Conclusion  
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 The use of native herbal and medicinal plants from China and Thailand as a means of 
treating community-acquired pneumonia and mitigating mild-to-moderate COVID-19 symptoms 
are shown to be a safe practice that yields successful results. The seven literature sources provide 
a foundation for further research that could be the basis of evidence-based practice interventions 
implemented in medical settings. The proposed research will advance the profession of nursing 
by understanding the substantial significance of nonpharmacological interventions using herbal 
and medicinal plants. Implementing this practice in rural areas eliminates the challenges of being 
isolated and having inaccessible medical resources, while potentially reducing the morbidity and 
mortality rate of these residents (especially those unvaccinated) which would otherwise lead to 
rapid health deterioration. 
 Beyond the knowledge acquired, important next steps in this process would be to 
determine the safety and efficacy rates of native Thai herbal plants used alongside Western 
medicine in mitigating COVID-19 symptoms, use of this practice among vulnerable populations 
such as children, geriatrics population, and pregnant women, and how these medicinal plants will 
be distributed to those who need them. 
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Appendix A: Literature Review Table 
Authors/Citation Purpose/Objective 
of Study 
Sample - Population 
of interest, sample 
size 





















Borwornpinyo, S., … 
Thitithanyanont, A. 
(2020). High-content 
screening of Thai 
medicinal plants 
reveals Boesenbergia 
rotunda extract and 
its component 
The purpose of their 




plants using the 
SARS-CoV-2 
nucleoprotein 
detection in Vero E6 
cells by measuring 
the amount of plaque 
reduction assay and 
dose-response 
analysis which 
indicated the viral 
suppression. 
Their sample tested 
122 Thai medicinal 
plants and their 
efficacy in 
suppressing SARS-
CoV-2 infectivity.  
Quantitative-
Experimental 






The natural extracts 
were pre-incubated 
with the virus before 
inoculation of the 




Natural extracts were 
introduced to the cell 




From the 122 Thai 
medicinal plants, 
three plants (extracts 
and purified 
compounds) were 
chosen to be tested 
further for their 
antiviral properties. 
From the extracts, 
two-fold cell 
dilutions were added 
into a cell culture 
after two hours of 
viral adsorption and 
the cell culture 
remained for 48 
hours. The cells were 
then stained with 
anti-SARS-CoV NP 
mAB and Alexa 
Fluor 488-labeled 
secondary antibody 
to be observed for 
their dose-response 
relationship.  


















The results from 
their study were 
thoroughly 
performed and 
collected as they 
measured the 
outcome of the 
chosen medicinal 






A large study sample 
of 122 potential 
medicinal plants to 
be tested was studied 
in preparation for 
their study.  
 
Besides testing the 
impact of B. rotunda 
extract and the 
panduratin A on the 
post-infection phase, 
they expanded the 
study and tested 
whether the two 
The authors stated 
that the rapid spread 
of COVID-19, “it has 
prompted us to 
develop, for the first 
time, a high-content 
screening platform” 
which has only been 
used with their study 
indicating a possible 






Sample - Population 
of interest, sample 
size 
Study Design Study Methods Major Finding(s) Strengths Limitations 






3.   
components would 
have an effect on 
pre-entry treatment 
which also showed 
successful results.  
Kasemsumran, S., 
Apiwatanapiwat, W., 






plant materials based 

















paniculate plant was 
used for this study.  
 
For this study, 170 
samples of the plant 
were obtained over 
two years which 
were categorized into 
four groups: aerial, 
stems, leaves, and 
stems mixed with 
leaves. The samples 
were collected from 












study to identify the 
effectiveness of the 
Andrographis  
paniculate plant was 




Fresh samples were 
made into a powder 
form being dried at 
50 degrees Celsius 
over a period of ten 
hours and then 
mechanically 
grinded. Each of the 
powdered samples 
was then placed into 
their respective test 




from the study may 
have been harvested 
during the vegetative 
period, but not more 
than 50% of the 
flowering. 
 
The leaves had the 
highest yield of AP1 
whereas the leaf and 
arterial parts 
contained the highest 
amount of AP3. 
 





success in classifying 
results in none and 
pretreatment patients.  
Their study consisted 
of a large sample size 
of 120 plant samples.  
 
The NIR technique 
can be used when 
running a sample as 
it does not require 
the sample to be 
extracted and does 
not run the risk of 
destroying or 
tampering with the 
sample either. 
A limited amount of 
research was 
performed and 
gained as the 
duration needed to 
run these samples 
took hours to weeks 
to finalize, some of 
their samples were 
destroyed due to the 
use of chemical 
substances and were 
costly due to the 
extensive types of 
equipment needed to 











Sample - Population 
of interest, sample 
size 
Study Design Study Methods Major Finding(s) Strengths Limitations 
Suphanburi, and Sa 
Kaeo.  
 
The leaf of the plant 
yielded the highest 
content of bioactive 
compounds.  
the researchers to 
create a method to 
quantify the contents 
with the NIR 
spectroscopy 
method.  
Liu, M., Gao, Y., 
Yuan, Y., Yang, K., 
Shi, S., Zhang, J., & 
Tian, J. (2020). 




Medicine for Corona 










The purpose of this 
study is to determine 
the efficacy and 





patients also known 
as “integrated 
medicine”.  
For this study, a total 
of 982 participants 




duration ranged from 
5 to 30 days with an 





created for interested 
participants 
including having to 
be 18 years of age or 
older and having to 
be diagnosed positive 
with COVID-19 by 
the laboratory.  
Quantitative 
experimental 
research performed  
From their intensive 
literature review 
search through six 
Chinese and English-
based databases 
regarding the use of 
integrated medicine 
on COVID-19 
positive patients, the 
researchers narrowed 
the information down 
to a total of 11 
studies. Four of the 
studies were 
randomized 
controlled trials and 
seven were case-
control studies which 
were assessed with 
the Cochrane Risk of 
Bias tool and 
Newcastle-Ottawa 
Scale respectively. 
In terms of 
quantitative-wise, the 
risk ratio (RR) was 
used for testing 
factors which fell 
into the dichotomous 
data category of 
having two 
categories of 
outcomes, while the 
weighted mean 
difference (WMD) 
was used for 
continuous testing 
factors such as the 
hospital stay which 
could result in a large  
range of outcomes 
such as a couple of 
days to years.  
 
Participants in the 
experimental group 
who received the 
integrated medicine 
To obtain the most 
relevant and reliable 
information from 
their literature review 
search, the authors 
narrowed the articles 
used from December 
01, 2019, to March 
24, 2020, which 
marked the discovery 
and peak of the 
spread of the SARS-
CoV-2 virus.  
 
Although clinical 
symptoms which are 
deemed as subjective 
data were collected 
from the participants, 
other objective data 
indicators were 
included such as 
measuring the C-
reactive protein 
count, white blood 
This study is the 







Due to the ranging 
treatment time 
frames, this could 
hinder their results as 
the participants did 
not receive the 
treatment for an 
equal duration of 
time which could 






Sample - Population 
of interest, sample 
size 
Study Design Study Methods Major Finding(s) Strengths Limitations 
 
As for the traditional 
Chinese medicine 
used for this trial, 
this included 
patented Chinese 
medicine such as the 
Shufeng Jiedu 
Capsule, Lianhua 
Qingwen granules as 
well as Chinese 
medicine compound 
drugs such as the 
QingFei TouXie 
FuZhengFang. 
The practices of 
Western medicine 




agents such as 
lopinavir and abidol, 
supportive care, and 
glucocorticoid 
therapy primarily to 
inhibit inflammation. 
Participants 
randomly selected to 
treatment had an 
overall better 
outcome than the 






and hospital stay rate 
(WMD= -1.991).  
 
Moreover, the use of 
integrated medicine 
for this particular 
group of patients 
showed the ability to 
mitigate symptoms 
of cough, fatigue, 
anorexia, fever, 
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of interest, sample 
size 
Study Design Study Methods Major Finding(s) Strengths Limitations 











combining TCM and 
Western medicine.  
Phumthum, M., 
Nguanchoo, V., & 
Balslev, H. (2021). 
Medicinal Plants 
Used for Treating 
Mild Covid-19 
Symptoms Among 
Thai Karen and 




9/fphar.2021.699897   
 
The purpose of this 
study is to identify 
which medicinal 
plants commonly 
used by the Thai 
Karen and Hmong 
community can also 
be used to treat mild 
symptoms of 
COVID-19.  
A total of 491 plant 
species were 
identified by both the 
Thai Karen and 
Hmong communities 
to alleviate 
symptoms of cough, 
diarrhea, sore throat, 
headache, and a rash 
which are labeled as 
mild symptoms by 
the WHO.  
 
Information 
regarding the use of 
ethnobotany was also 
obtained through 
literature review 






roles as local healers 
in the communities 
primarily using 
medicinal plants 
were interviewed and 
obtained others 
through a snowball 
sampling.  
The study was 
conducted through 
literature reviews as 
well as field 
interviews of the 
residents in the Thai 




From the medicinal 
plants identified in 
their study, fever was 
the most commonly 
treated symptom, 
then cough, diarrhea, 
muscle pain, skin 
rash, headache, then 





received the lowest 
reports among the 
Hmong and Karen 
communities.  
Because the authors 
used articles in their 
literature review 
which dated back to 
1999, they decided to 
obtain more relevant 
data about mild 
symptoms in the 
Hmong and Karen 
community in 2020. 
They used both 
previously published 
data and their data to 
strengthen the use of 
medicinal plants in 






regarding signs and 
symptoms of mild 
COVID-19, this is 
subjective data being 
obtained as everyone 
may have their 
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of interest, sample 
size 
Study Design Study Methods Major Finding(s) Strengths Limitations 
from thirty-one 
Karen and nineteen 
Hmong villages as 
well as six new 
Hmong villages as 
well as 1230 overall 
respondents (675 




plants which were 
used to treat fever, 
cough, diarrhea, 
muscle pain, rash, 
headache, 
conjunctivitis, and 
sore throat, meaning 
other mild COVID-
19 sign and 
symptoms (such as 
respiratory) 
identified by the 
WHO were not 
included in their 
study. 
Wen, L., Zhou, Z., 
Jiang, D., & Huang, 
K. (2020). Zhonghua 
wei zhong bing ji jiu 






efficacy of Xuebijing 
injections in severe 
COVID-19 patients 
(controlled, 50mL, 
and 100mL dosages). 
Sixty clinically 
diagnosed COVID-
19 patients in severe 
conditions were 
admitted to the 
Changsha Public 
Health Treatment 
Center in Changsha, 
China between 




The sixty participants 
were evenly divided 
into three groups, 
each with twenty 
participants, of those 
who received the 








Across the three 
groups after the 
treatment period was 
completed, a 
decrease in C-
reactive protein and 
erythrocyte 
sedimentation rate 
was observed, while 
the lymphocyte and 
white blood cell 




injection had more 
significantly 
improved results in 
the laboratory 
indicators mentioned 
above as well as their 
APACHE II score 
which was lower 
than the control and 
The study did not 
indicate the results 
(improved) by 
category and rather 
in a manner which 





Sample - Population 
of interest, sample 
size 
Study Design Study Methods Major Finding(s) Strengths Limitations 
The study was 
conducted over seven 
days, with those in 
the experimental 
group receiving their 
respective dosage of 
Xuebijing injection 




Xiong, X., Wang, P., 
Su, K., Cho, W. C., 















analysis depict the 
use of traditional 
Chinese medicine, in 
particular Chinese 
herbal medicine, to 
treat COVID-19 
positive patients in 
mainland China.  
A total of eighteen 
randomized 
controlled trials were 





requiredt to be a 
participant in their 
study is to be 
diagnosed with 
COVID-19 without 
any limitations on 
nationality, gender, 
and age.  
A quantitative study 
was performed 
The study was 
conducted in the 
manner of a  
quantitative study of 
a randomized 
controlled trial with 





and/or a combination 
of Chinese herbal 
medicine placebo 
while the treatment 
(experimental) group 





Western medicine.  
the risk reduction 
rate was compared 






cough among 240 
CHM and 182 CWM 
participants of an RR 
value of 1.50, fever 
being significantly 
reduced within 433 
patients  with a 
weight mean 
difference of -0.60, 
fatigue reduction 
among 167 patients 
in CHM and 140 in 
CWM with a RR 




measured in the form 
of a lung CT as well 
as other measures 




This study is the 
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within 141 CHM 
participants with a 
weight mean 
difference of -6.60 
Zheng, R., Wang, H., 
Liu, Z., Wang, X., 
Li, J., Lei, X., Fan, 
Y., Liu, S., Feng, Z., 
& Shang, H. (2019). 
A real-world study 




monitoring based on 
93 hospitals (31,913 
cases). Annals of 
translational 
medicine, 7(6), 117. 
https://doi.org/10.210
37/atm.2018.09.26   
The purpose of this 
study is to determine 
the efficacy and 
safety level of using 
traditional Chinese 
medicine injections 
on those with 
community-acquired 
pneumonia. 
The population of 










description seems to 
be very broad, they 
narrowed down the 
participants who 
would qualify to take 
part in this study by 
having either of the 
criteria listed. For 
example, to be 
declared as a 
“critically severe 
patient” they have to 





reviews from various 
databases such as 
PubMed, Wang Fang 
Database, and 
Cochran Library) and 
quantitative study 
(randomized 


















2. Controls: Include 
no treatment, 
placebo, or other 
active treatment 
recommended by the 
guideline. 
3. Outcomes: We 
provide the following 
results to reflect the 
efficacy and safety of 
From various studies, 












Additionally, the use 





and reduced the risk 
of septic shock.   






regarding the safety 







Their study aims to 
look at the topic on a 
holistic level 
including researching 
the effective rate, all-
cause mortality 
clinical recovery 
time, and negative 
time of novel 
coronavirus nucleic 






positive results, there 
has not been any 
research on whether 





nucleic acid.  
 
There were 96 cases 
of adverse reactions 
to the Xuebijing 
injection which 
equates to 0.3% of 
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of interest, sample 
size 
Study Design Study Methods Major Finding(s) Strengths Limitations 
ventilation, shock, or 
organ failure needing 





4. Main results: 
effective rate and all-
cause mortality. 
5. Secondary results: 
clinical recovery 
time, negative time 




intensive care unit 
length of stay, dose-
response of injection, 
and adverse event 
rate. 
evidence-based 
practice studies and 
treatment.  
 
